Quintiles and ArgoMed to sell prostate device:
This article was originally published in Clinica
Executive Summary
Quintiles Transnational has agreed a commercialisation alliance with Israeli company ArgoMed to develop its FDA-approved Thermoflex water-induced thermotherapy system to treat benign prostatic hyperplasia (BPH). Quintiles corporate ventures business, PharmaBio Development, will provide credit for ArgoMed to organise a US sales force and market the device. In addition, PharmaBio will take equity in the company, while Innovex, Quintiles' commercialisation unit, will deploy the sales force where it is required by ArgoMed. Innovex claims that it has created 19 sales forces and launched 19 new products over the past five years.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.